25 impacts in 25 years: Illumina and the evolution of genomics

In this application note, Illumina highlights the upcoming advancements in genomics. Over the next 25 years, it predicts breakthroughs in cardiovascular disease testing, AI-driven drug target discovery, and expanded testing capabilities for tuberculosis-affected countries. Its customers are also making strides in research for autism spectrum disorder, PTSD, and diabetes. In the note, Illumina also celebrates its quarter-century involvement in the global genomics movement and looks forward to further enhancing patient outcomes through the power of genomics.